Treatment of Splenic Vein Thrombosis in Symptomatic Acute Splanchnic Vein Thrombosis Without Liver Cirrhosis
Clinical Scenario
This protocol addresses patients with symptomatic acute splanchnic vein thrombosis who do not have underlying liver cirrhosis and present with no signs of active bleeding — a population where the approach to anticoagulation is distinct from that used in cirrhotic patients.
Treatment Approach
Full therapeutic anticoagulation — with direct oral anticoagulants (DOACs) as the preferred agent class — is the foundation of management. The appropriate duration and whether to extend therapy beyond the initial course depends on the patient's individual clinical trajectory. The complete protocol specifies the criteria and alternatives.
Treatment Goal
Achieve the highest possible vessel recanalization to reduce splanchnic hypertension and associated bleeding risk.
References
DOI: 10.1111/jth.14836
- In non-cirrhotic patients with symptomatic acute splanchnic vein thrombosis who have no signs of active bleeding, we suggest full therapeutic dose of DOACs, and consider LMWH and VKAs with INR range of 2.0-3.0 in patients who cannot tolerate or have contraindications for DOACs.
- 3 to 6-mo anticoagulation irrespective of thrombosis extension and underlying risk factors
- Longer course or indefinite anticoagulation if: Thrombosis progression or recurrence after treatment discontinuation; Unprovoked splanchnic vein thrombosis; Persistent thrombotic risk factor
- Treatment of occlusive or non-occlusive acute splanchnic vein thrombosis aims to prevent intestinal infarction or ischemia, and achieve the highest possible vessel recanalization to reduce splanchnic hypertension and bleeding risk.